Enhanced Curcumin Compositions for Neurological Disorders

Publication ID: 24-11857594_0001_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Curcumin Compositions for Neurological Disorders,” Published Technical Disclosure No. 24-11857594_0001_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857594_0001_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,594.

Summary of the Inventive Concept

This inventive concept relates to improved curcumin compositions and methods for treating neurological disorders, enhancing the original patent's limitations by increasing bioavailability, brain penetration, and efficacy while improving stability and shelf life.

Background and Problem Solved

The original patent disclosed curcumin compositions as NK3 antagonists, but these compositions had limitations in terms of bioavailability, brain penetration, and efficacy. The new inventive concept addresses these limitations by introducing novel formulations, delivery systems, and compositions that overcome the existing drawbacks.

Detailed Description of the Inventive Concept

The new inventive concept comprises four main aspects: 1) a method for treating neurological disorders using a curcumin composition with improved bioavailability, 2) a system for delivering curcumin compositions to the brain using nanoparticle formulations, 3) a curcumin composition with a synergistic ratio of diferuloylmethane to demethoxycurcumin to bis-demethoxycurcumin, and 4) a method for preparing curcumin compositions with improved stability and shelf life using liposome encapsulation. These aspects work in tandem to provide a more effective and efficient treatment for neurological disorders.

Novelty and Inventive Step

The new claims introduce novel formulations, delivery systems, and compositions that significantly improve the original patent's limitations, providing a non-obvious solution to the existing drawbacks. The inventive concept's novelty lies in the specific combinations of components, ratios, and formulations that achieve the desired enhancements.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include different nanoparticle formulations, varying synergistic ratios, and diverse liposome encapsulation methods. These variations can be tailored to specific neurological disorders, patient populations, or treatment regimens, ensuring broad conceptual coverage.

Potential Commercial Applications and Market

The enhanced curcumin compositions and methods have significant commercial potential in the treatment of neurological disorders, such as Alzheimer's disease, Parkinson's disease, and depression. The target market includes pharmaceutical companies, biotechnology firms, and healthcare providers seeking more effective and efficient treatments for these disorders.

CPC Classifications

SectionClassGroup
A A61 A61K36/9066
A A61 A61K31/26
A A61 A61K36/82
A A61 A61P15/12

Field of Art

Pharmaceutical compositions, neurological disorder treatments, and natural product-based therapeutic formulations, with expertise in receptor pharmacology, drug delivery systems, and nutraceutical composition optimization

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical scientist or biochemical engineer with advanced degree, experience in drug formulation, knowledge of receptor pharmacology, familiarity with natural product extraction techniques, and understanding of nanoparticle and liposomal delivery technologies

Obviousness Rationale

A PHOSITA would recognize that the PTD's variations represent predictable extensions of the source patent's curcumin composition teachings, utilizing standard pharmaceutical engineering techniques to enhance bioavailability, delivery, and therapeutic efficacy through well-established methodological approaches in drug development.

Obvious Combinations & Variations

Source Patent Element
Curcumin composition with synergistic ratios of multiple components
PTD Variation
Modified synergistic ratio of diferuloylmethane to demethoxycurcumin to bis-demethoxycurcumin
Obviousness Reasoning
Routine optimization of component ratios through systematic experimentation, representing a predictable variation within known compositional design parameters
Source Patent Element
Combination therapeutic composition targeting neurological conditions
PTD Variation
Nanoparticle formulation enhancing brain penetration by 30%
Obviousness Reasoning
Well-known drug delivery technique of using nanoparticles to improve pharmacokinetic properties, representing a standard approach in pharmaceutical engineering
Source Patent Element
Natural product-based therapeutic composition
PTD Variation
Liposome encapsulation method for improving stability and shelf life
Obviousness Reasoning
Conventional pharmaceutical technique for stabilizing active compounds, representing a predictable solution to preserving natural product efficacy
Source Patent Element
Curcumin composition with multiple active components
PTD Variation
Controlled release profile targeting 80% release within 2 hours
Obviousness Reasoning
Standard pharmaceutical formulation strategy for optimizing drug release kinetics, utilizing known sustained-release technologies
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857594, a person having ordinary skill in the art would find the variations disclosed in the present publication to represent obvious modifications achievable through routine pharmaceutical engineering techniques, thereby rendering subsequent claims directed to similar compositional and delivery strategies anticipated and non-patentable under 35 U.S.C. ยง 103.

Original Patent Information

Patent NumberUS 11,857,594
TitleCurcumin compositions and methods of use as an NK3 antagonist
Assignee(s)JDS Therapeutics, LLC